Cefdinir

Antibacterial effect It has a wide antibacterial spectrum against Gram-positive and Gram-negative bacteria, especially against Staphylococcus and Streptococcus among Gram-positive bacteria. It has stronger antibacterial activity than previous oral cephalosporins, and its mode of action is bactericidal. It is stable to β-lactamase produced by various bacteria, and also has excellent antibacterial activity against β-lactamase producing bacteria. The mechanism of action is to prevent the synthesis of bacterial cell wall. It has strong affinity for penicillin binding protein (PBP) 1 (1a, 1bs), 2, and 3, but the active sites for different bacteria are different.

The following infections caused by strains of Staphylococcus, Streptococcus, Pneumococcus, Peptostreptococcus, Propionibacterium, Neisseria gonorrhoeae, Moraxella catarrhalis, Escherichia coli, Klebsiella, Proteus mirabilis, Providencia, Haemophilus influenzae, etc. that are sensitive to cefdinir: pharyngitis, tonsillitis, acute bronchitis, pneumonia; otitis media, sinusitis; pyelonephritis, cystitis, gonococcal urethritis; adnexitis, intrauterine infection, vestibular glanditis; mastitis, perianal abscess, secondary infection of trauma or surgical wound; folliculitis, furuncle, furuncle, carbuncle, infectious impetigo, erysipelas, cellulitis, lymphangitis, paronychia, subcutaneous abscess, atheroma infection, chronic pyoderma; blepharitis, sty, tarsal glanditis.

Among the 13,715 patients treated with this product, 354 cases (2.58%) of adverse reactions (including abnormal laboratory data) were reported. The main adverse reactions were gastrointestinal symptoms (110 cases, 0.80%), such as diarrhea or abdominal pain; skin symptoms (31 cases, 0.23%), such as rash or itching. The main abnormal laboratory data included increased alanine aminotransferase (126 cases, 0.92%) and aspartate aminotransferase (89 cases, 0.65%); eosinophilia (41 cases, 0.30%). 1. Clinical adverse reactions 0.1% ≤ Incidence ‹5% Incidence ‹0.1% Incidence unknown Allergy Rash Urticaria, itching, fever, edema Erythema Hematology Eosinophilia Neutrophils

Patients with a history of shock should not use this product. Patients with a history of allergy to penicillin or cephalosporin should use it with caution.

Caution is required when using this product with the following drugs. Drug signs, symptoms, treatment mechanisms and risk factors Iron preparations may reduce the absorption of cefdinir by about 10%, so it is recommended to avoid co-administration with such drugs. If co-administration cannot be avoided, the interval between the two doses should be greater than 3 hours This product can combine with iron ions in the intestine to form a complex that is difficult to absorb. Warfarin potassium The effect of warfarin potassium may be enhanced, but there are no reports of interaction between the two. This product may inhibit the production of vitamin K by intestinal bacteria. Antacids (containing aluminum or magnesium) can reduce the absorption of cefdinir and weaken its effect, so antacids should be used 2 hours after taking this product. The mechanism is not clear.

Keep in a dark place (avoid light and not exceed 20℃) and sealed.

Zhejiang Yongning Pharmaceutical Co., Ltd.

• Founded in:

  1990-01-01

• Address:

  No. 4 Meihuajing Road, Huangyan, Taizhou City, Zhejiang Province

• Tax NO.:

  913310001481462415

• Registered Funds:

  153.125 million yuan

• Website:

  Log in to view

• Email:

  Log in to view